12 RESULTS
COMMENT We do not know which information FDA requested of Biogen. I do not believe the new data from the ongoing open-label extension trial on aducanumab represent significant information because of the uncontrolled nature of the study. Rather, I can speculate ...
COMMENT The recent work of Minhas and colleagues unveils the crucial role of myeloid prostaglandin EP2 signaling in the bioenergetic dysfunction processes that occur during aging. The authors demonstrated that in aged mice, both central and peripheral inhibition ...
COMMENT I agree with Tristan Massie regarding the issues he raised in the statistical section of the FDA/Biogen document, and with David Knopman and colleagues regarding the methodological and clinical issues they raised in their recent article published by ...
COMMENT I offer a discussion point on the treatment effects of the aducanumab high dose in the EMERGE study. They were: +0.50 points on MMSE (cognition)-1.4 points on ADAS-Cog (cognition)-0.40 points on CDR-SB (clinical status) +1.7 points on ADCS-ADL-MCI ...
COMMENT The last week saw a debate on potential reasons to explain the divergent outcome on the primary variable (CDR-SB) emerging from the new analyses of the two interrupted (apparently identical) Phase 3 studies on aducanumab. Compared with the placebo group, ...
COMMENT The results of the 18-month study with BAN2401 in 856 subjects with prodromal AD or mild AD has raised a lot of interest and prudent hope. We know very little about the trial and will learn more in a couple of weeks at AAIC. In the meantime, will can make ...
COMMENT Chen and colleagues have proposed a new pathophysiological role for AICD in PD pathogenesis. They showed that LRRK2 phosphorylated APP at Thr668, and that this further promoted the nucleus transcriptional activity of AICD, and its translocation to the ...
COMMENT Lilly researchers set up EXPEDITION3 when a subgroup analysis of EXPEDITION1 and EXPEDITION2 trials suggested a benefit only for patients with mild disease. Why did EXPEDITION3 not confirm apparent positive findings of the two prior trials in mildly ...
COMMENT In this paper on the aducanumab Phase 1b study in prodromal and mild AD patients, the data on plaque removal are quite encouraging. As pointed out on AlzForum, the initial positive cognitive data need to be confirmed in the ongoing Phase 3 studies, and I ...
COMMENT This study was well-conducted and is elegant because it shows consistent effects of the drug citalopram in transgenic mice and in humans. Regarding the potential use of citalopram in Alzheimer’s disease patients, Mark Mattson correctly points out that ...
COMMENT The community as a whole—independent researchers, colleagues and competitors alike—are eagerly awaiting a successful AD trial, hence there is widespread disappointment about the results of this 52-week study of PBT2 in 42 prodromal AD or mild AD patients. ...
COMMENT Soluble β amyloid has a beneficial physiological role for the normal functioning of neurons. In the AD brain, the increase in soluble β amyloid concentrations, mainly via a decrease in its clearance, could simply represent the brain's attempt to ...
